Company Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology.
The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company’s lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN).
It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type.
In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer.
Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration.
The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
| Country | United States |
| Founded | 2010 |
| IPO Date | Mar 9, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Lan Huang |
Contact Details
Address: 100 Campus Drive, 4th Floor, Suite 410 Florham Park, New Jersey 07932 United States | |
| Phone | 646 305 6387 |
| Website | beyondspringpharma.com |
Stock Details
| Ticker Symbol | BYSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001677940 |
| CUSIP Number | G10830100 |
| ISIN Number | KYG108301006 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lan Huang Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Dr. June Lu Ph.D. | Chief Scientific Officer |
| Joy Jia | Vice President of Finance |
| Stephen Kilmer | Head of Investor Relations |
| Dr. John Mao Ph.D. | Senior Vice President of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 13, 2026 | 10-Q | Quarterly Report |
| May 13, 2026 | 8-K | Current Report |
| Mar 25, 2026 | 10-K | Annual Report |
| Mar 25, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Dec 15, 2025 | 8-K | Current Report |
| Nov 21, 2025 | 8-K | Current Report |
| Nov 17, 2025 | 424B5 | Filing |